Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial

Levi S. Downs, Justin C. Chura, Peter A. Argenta, Patricia L. Judson, Rahel Ghebre, Melissa A. Geller, Linda F. Carson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: (1) To determine the response rate of advanced, recurrent, or persistent carcinoma of the cervix to ifosfamide, paclitaxel, and carboplatin chemotherapy; (2) to determine the progression free interval and survival rate in patients treated with this regimen; (3) to describe the toxicities associated with this regimen; and (4) to evaluate the quality of life of patients while on treatment. Methods: Eligible patients had histologically proven stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Chemotherapy was given on day 1 of a 28-day cycle: mesna (600 mg/m2) prior to ifosfamide (2 g/m 2), paclitaxel (175 mg/m2), carboplatin (AUC 5). Response rates were determined according to RECIST criteria. Toxicity was graded according the National Cancer Institute's common toxicity criteria. Quality of life measurements were obtained using the FACT-Cx. Results: Twenty-eight patients participated in this study, with 21 evaluable for response rate. Overall, 7 patients (33%) had a demonstrated objective response (4 complete responses, 3 partial responses). Stable disease was documented in 3 patients. The overall median survival for all patients was 10 months. Median progression free survival for evaluable patients was 5.0 months. Bone marrow suppression was the most common toxicity. There were no negative effects of this treatment regimen on quality of life assessments. Conclusion: Ifosfamide, paclitaxel, and carboplatin is an effective regimen in treating advanced or recurrent carcinoma of the cervix and has an acceptable toxicity profile.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalGynecologic oncology
Volume120
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Ifosfamide
Carboplatin
Paclitaxel
Cervix Uteri
Carcinoma
Quality of Life
Disease-Free Survival
Mesna
Drug Therapy
National Cancer Institute (U.S.)
Area Under Curve
Radiotherapy
Therapeutics
Survival Rate
Bone Marrow
Survival

Keywords

  • Carboplatin
  • Cervical cancer
  • Ifosfamide
  • Paclitaxel
  • Phase II trial

Cite this

Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix : A phase II trial. / Downs, Levi S.; Chura, Justin C.; Argenta, Peter A.; Judson, Patricia L.; Ghebre, Rahel; Geller, Melissa A.; Carson, Linda F.

In: Gynecologic oncology, Vol. 120, No. 2, 01.02.2011, p. 265-269.

Research output: Contribution to journalArticle

@article{631781bbc88c4efbbf870f624c9f4a4d,
title = "Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial",
abstract = "Objectives: (1) To determine the response rate of advanced, recurrent, or persistent carcinoma of the cervix to ifosfamide, paclitaxel, and carboplatin chemotherapy; (2) to determine the progression free interval and survival rate in patients treated with this regimen; (3) to describe the toxicities associated with this regimen; and (4) to evaluate the quality of life of patients while on treatment. Methods: Eligible patients had histologically proven stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Chemotherapy was given on day 1 of a 28-day cycle: mesna (600 mg/m2) prior to ifosfamide (2 g/m 2), paclitaxel (175 mg/m2), carboplatin (AUC 5). Response rates were determined according to RECIST criteria. Toxicity was graded according the National Cancer Institute's common toxicity criteria. Quality of life measurements were obtained using the FACT-Cx. Results: Twenty-eight patients participated in this study, with 21 evaluable for response rate. Overall, 7 patients (33{\%}) had a demonstrated objective response (4 complete responses, 3 partial responses). Stable disease was documented in 3 patients. The overall median survival for all patients was 10 months. Median progression free survival for evaluable patients was 5.0 months. Bone marrow suppression was the most common toxicity. There were no negative effects of this treatment regimen on quality of life assessments. Conclusion: Ifosfamide, paclitaxel, and carboplatin is an effective regimen in treating advanced or recurrent carcinoma of the cervix and has an acceptable toxicity profile.",
keywords = "Carboplatin, Cervical cancer, Ifosfamide, Paclitaxel, Phase II trial",
author = "Downs, {Levi S.} and Chura, {Justin C.} and Argenta, {Peter A.} and Judson, {Patricia L.} and Rahel Ghebre and Geller, {Melissa A.} and Carson, {Linda F.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.ygyno.2010.10.020",
language = "English (US)",
volume = "120",
pages = "265--269",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix

T2 - A phase II trial

AU - Downs, Levi S.

AU - Chura, Justin C.

AU - Argenta, Peter A.

AU - Judson, Patricia L.

AU - Ghebre, Rahel

AU - Geller, Melissa A.

AU - Carson, Linda F.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objectives: (1) To determine the response rate of advanced, recurrent, or persistent carcinoma of the cervix to ifosfamide, paclitaxel, and carboplatin chemotherapy; (2) to determine the progression free interval and survival rate in patients treated with this regimen; (3) to describe the toxicities associated with this regimen; and (4) to evaluate the quality of life of patients while on treatment. Methods: Eligible patients had histologically proven stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Chemotherapy was given on day 1 of a 28-day cycle: mesna (600 mg/m2) prior to ifosfamide (2 g/m 2), paclitaxel (175 mg/m2), carboplatin (AUC 5). Response rates were determined according to RECIST criteria. Toxicity was graded according the National Cancer Institute's common toxicity criteria. Quality of life measurements were obtained using the FACT-Cx. Results: Twenty-eight patients participated in this study, with 21 evaluable for response rate. Overall, 7 patients (33%) had a demonstrated objective response (4 complete responses, 3 partial responses). Stable disease was documented in 3 patients. The overall median survival for all patients was 10 months. Median progression free survival for evaluable patients was 5.0 months. Bone marrow suppression was the most common toxicity. There were no negative effects of this treatment regimen on quality of life assessments. Conclusion: Ifosfamide, paclitaxel, and carboplatin is an effective regimen in treating advanced or recurrent carcinoma of the cervix and has an acceptable toxicity profile.

AB - Objectives: (1) To determine the response rate of advanced, recurrent, or persistent carcinoma of the cervix to ifosfamide, paclitaxel, and carboplatin chemotherapy; (2) to determine the progression free interval and survival rate in patients treated with this regimen; (3) to describe the toxicities associated with this regimen; and (4) to evaluate the quality of life of patients while on treatment. Methods: Eligible patients had histologically proven stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Chemotherapy was given on day 1 of a 28-day cycle: mesna (600 mg/m2) prior to ifosfamide (2 g/m 2), paclitaxel (175 mg/m2), carboplatin (AUC 5). Response rates were determined according to RECIST criteria. Toxicity was graded according the National Cancer Institute's common toxicity criteria. Quality of life measurements were obtained using the FACT-Cx. Results: Twenty-eight patients participated in this study, with 21 evaluable for response rate. Overall, 7 patients (33%) had a demonstrated objective response (4 complete responses, 3 partial responses). Stable disease was documented in 3 patients. The overall median survival for all patients was 10 months. Median progression free survival for evaluable patients was 5.0 months. Bone marrow suppression was the most common toxicity. There were no negative effects of this treatment regimen on quality of life assessments. Conclusion: Ifosfamide, paclitaxel, and carboplatin is an effective regimen in treating advanced or recurrent carcinoma of the cervix and has an acceptable toxicity profile.

KW - Carboplatin

KW - Cervical cancer

KW - Ifosfamide

KW - Paclitaxel

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=79251601167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251601167&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.10.020

DO - 10.1016/j.ygyno.2010.10.020

M3 - Article

C2 - 21145100

AN - SCOPUS:79251601167

VL - 120

SP - 265

EP - 269

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -